Can LABA be used alone as monotherapy in patients with persistent asthma?

Long-acting beta-agonists (LABAs) should not be used alone as monotherapy in patients with persistent asthma due to the risk of increased asthma-related morbidity and mortality. LABAs are effective bronchodilators that provide prolonged relief of bronchospasm; however, they do not address the underlying inflammation characteristic of asthma.

In the management of persistent asthma, inhaled corticosteroids (ICS) are typically the first-line treatment for controlling inflammation and preventing exacerbations. When LABAs are combined with inhaled corticosteroids, they can provide a synergistic effect, improving overall asthma control. This combination is recommended to ensure that patients receive both long-term bronchodilation and anti-inflammatory treatment.

The primary concern with using LABAs alone is that they may mask the symptoms of worsening asthma, leading to delays in receiving appropriate anti-inflammatory treatment. Therefore, for patients with persistent asthma, the standard approach is to use LABAs only in conjunction with inhaled corticosteroids.